tiprankstipranks
Trending News
More News >
Medical Developments International Limited (AU:MVP)
ASX:MVP
Advertisement

Medical Developments International Limited (MVP) AI Stock Analysis

Compare
9 Followers

Top Page

AU:MVP

Medical Developments International Limited

(Sydney:MVP)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
AU$0.50
▼(-30.56% Downside)
The overall stock score of 51 reflects significant challenges in financial performance, particularly in profitability and cash flow management. While technical analysis shows a positive price trend, the extremely high P/E ratio suggests overvaluation concerns. The absence of earnings call and corporate events data means these factors did not influence the score.

Medical Developments International Limited (MVP) vs. iShares MSCI Australia ETF (EWA)

Medical Developments International Limited Business Overview & Revenue Model

Company DescriptionMedical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease; Penthrox, a trauma and emergency pain relief product; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, oxygen resuscitation kits, oxygen therapy masks, and resuscitators. The company was incorporated in 2003 and is headquartered in Scoresby, Australia.
How the Company Makes MoneyMedical Developments International Limited generates revenue through the sale of its medical products across various markets. The primary revenue stream comes from the distribution of the Penthrox inhaler, which is in high demand in emergency medical settings due to its effectiveness and ease of use. The company also earns income from its respiratory and veterinary product lines, which are sold to healthcare facilities, clinics, and veterinary practices. MVP's earnings are further bolstered by strategic partnerships and distribution agreements that expand its market reach globally. The company may also engage in research and development collaborations, contributing to its revenue through the development of new and improved medical technologies.

Medical Developments International Limited Financial Statement Overview

Summary
Medical Developments International Limited exhibits a mixed financial performance. While there is some revenue growth and a strong gross profit margin, profitability remains a significant challenge. The balance sheet is stable with low leverage, but cash flow issues are a major concern, indicating potential liquidity risks. The company needs to focus on improving profitability and cash flow management to enhance its financial health.
Income Statement
55
Neutral
The company has shown a modest revenue growth rate of 2.63% in the latest year, indicating some positive momentum. However, profitability remains a concern with a very low net profit margin of 0.24% and an EBIT margin of 0.36%. The gross profit margin is relatively strong at 75.35%, suggesting efficient production or service delivery. Overall, while there are signs of revenue growth, the company struggles with profitability.
Balance Sheet
65
Positive
The balance sheet is relatively strong with a low debt-to-equity ratio of 0.036, indicating low financial leverage and risk. The return on equity is minimal at 0.17%, reflecting challenges in generating returns for shareholders. The equity ratio is healthy, suggesting a stable financial structure. Overall, the balance sheet shows financial stability but limited profitability.
Cash Flow
40
Negative
The cash flow situation is concerning, with negative operating cash flow and free cash flow. The free cash flow growth rate is significantly negative at -92.85%, indicating deteriorating cash generation capabilities. The free cash flow to net income ratio is high at 11.30, suggesting that cash flow issues are not aligned with reported net income. Overall, the cash flow statement highlights significant challenges in cash generation and management.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue39.06M39.06M33.15M32.34M21.94M25.27M
Gross Profit29.43M29.43M24.37M-2.52M-3.06M16.67M
EBITDA1.67M1.67M-29.45M-4.28M-12.86M-11.11M
Net Income94.00K94.00K-40.99M-5.61M-12.41M-12.56M
Balance Sheet
Total Assets66.40M66.40M59.16M109.49M101.36M100.17M
Cash, Cash Equivalents and Short-Term Investments17.84M17.84M9.73M24.66M20.40M36.28M
Total Debt1.99M1.99M2.29M2.56M2.81M3.05M
Total Liabilities11.29M11.29M13.43M28.17M44.06M31.87M
Stockholders Equity55.10M55.10M45.73M81.31M57.30M68.30M
Cash Flow
Free Cash Flow-486.00K-486.00K-13.95M-24.16M-15.94M-15.37M
Operating Cash Flow-43.00K-43.00K-10.78M-16.50M-10.72M-8.81M
Investing Cash Flow-1.04M-1.04M-3.17M-7.67M-5.21M-6.56M
Financing Cash Flow8.68M8.68M-807.00K28.06M142.00K36.12M

Medical Developments International Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.72
Price Trends
50DMA
0.65
Positive
100DMA
0.63
Positive
200DMA
0.61
Positive
Market Momentum
MACD
0.02
Negative
RSI
57.72
Neutral
STOCH
80.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Positive. The current price of 0.72 is above the 20-day moving average (MA) of 0.68, above the 50-day MA of 0.65, and above the 200-day MA of 0.61, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 57.72 is Neutral, neither overbought nor oversold. The STOCH value of 80.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
AU$46.39M12.967.64%2.86%0.13%-12.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
AU$80.55M715.000.19%17.82%
41
Neutral
AU$19.03M-218.38%-47.30%82.53%
41
Neutral
AU$24.40M-35.58%45.30%-24.18%
39
Underperform
AU$4.26M16.0069.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MVP
Medical Developments International Limited
0.72
0.29
67.44%
AU:LGP
Little Green Pharma Ltd.
0.14
-0.02
-12.50%
AU:BOD
Bod Australia Ltd
0.02
0.00
0.00%
AU:AGH
Althea Group Holdings Ltd.
0.02
-0.03
-60.00%
AU:IDT
IDT Australia Limited
0.06
-0.06
-50.00%
AU:VIT
Cronos Australia Ltd.
0.07
-0.04
-36.36%

Medical Developments International Limited Corporate Events

Medical Developments International Achieves Positive Cash Flow and Expands Penthrox Market
Jul 31, 2025

Medical Developments International Limited reported a positive operating cash flow for the second half of FY25, with significant improvements in revenue and financial position. The company saw increased demand for Penthrox, particularly in Australian hospitals, and successfully transitioned its distribution in France and Switzerland to partners. Despite a slight decline in respiratory revenue due to seasonal factors, the overall financial performance was bolstered by higher pricing and volume growth. The company plans to continue investing in strategic initiatives to accelerate the adoption of Penthrox and improve operational efficiencies.

The most recent analyst rating on (AU:MVP) stock is a Hold with a A$0.71 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Issues New Performance Rights
Jun 2, 2025

Medical Developments International Limited announced the issuance of 2,687,635 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize its workforce and align their interests with corporate performance, potentially impacting its operational efficiency and market positioning.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Appoints New Director to Drive Strategic Growth
May 30, 2025

Medical Developments International Limited announced the resignation of Richard Betts and the appointment of Paul Townsend to its Board, effective 30 May 2025. Paul Townsend, a seasoned finance leader with extensive experience across multiple sectors, will assume the role of Chair of the Audit & Risk Committee. His background in driving business outcomes and leading major organizational changes is expected to support MVP’s strategic growth objectives. The company anticipates that Townsend’s expertise will aid in unlocking its full potential and achieving long-term global growth.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 11, 2025